ERBB2 and cancer: HCC1954 cells were also less sensitive to both agents in cell culture (Fig. 2C) and may reflect reduced efficacy of PI3Kα inhibitor monotherapy in HER2+ cancers due to compensatory HER3 activation (30, 31).